The effect of adjuvant immunotherapy on tumor recurrence after segmental resection of carcinogen-induced Wistar/Furth primary bowel adenocarcinomas

Journal Article · Fri Jan 01 00:00:00 EST 1982 · J. Immunol.; (United States)

OSTI ID:5637569

Steele, G Jr; Harte, P J; Rayner, A A; Corson, J M; Madara, J; Munroe, A E; King, V P; Wilson, R E

Primary bowel tumors were induced in Wistar/Furth (W/Fu) rats by 16 weekly subcutaneous injections of 1,2-Dimethylhydrazine (DMH). After ''curative'' resection of primary adenocarcinomas of the colon, 75% of control rats who received no further treatment developed local or regional recurrence within 22 wk. In 4 separate experiments, rats immunized after primary tumor resection by 3 weekly subcutaneous inoculations of 1 x 10/sup 6/ irradiated (10,000 rad) DMH-W15 sarcoma cells (no tumor-associated antigens cross-reacting with bowel adenocarcinomas) developed recurrent tumor at a rate similar to the controls. By contrast, after primary bowel tumor resection, rats immunized with DMH-W-163 colon adenocarcinoma (possessing tumor-associated antigens cross-reactive with W/Fu bowel adenocarcinomas) showed a consistently reduced rate of local or regional recurrence compared to either of the controls (x/sup 2/ = 4.62, p < 0.05) or the rats immunized with sarcomas (X/sup 2/ = 5.42, p < 0.05)= 4.62, p < 0.05). By 22 wk after primary tumor resection, only 35% of the DMH-W-163-immunized animals in each of the 4 experiments showed recurrence. No deaths from recurrences were note in any of the experimental groups after this time, and selected animals sacrificed in the immunized groups up to 30 wk after primary tumor resection were documented to be disease-free. Protection against tumor recurrence was, therefore, a reflection of increased disease-free survival. No change in the effectiveness of immunoprotection in this model could be demonstrated after resection of less invasive primary tumors. These data reflect the utility of a new model in which modification of the natural history of individual primary bowel adenocarcinomas can be examined. The similarities and differences between this system and humans with colon cancer are discussed.

• Research Organization: Harvard Medical School, Boston, MA
• OSTI ID: 5637569
• Journal Information: J. Immunol.; (United States), Vol. 128:1
• Country of Publication: United States
• Language: English

Related Subjects

63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
IMMUNE REACTIONS
BIOLOGICAL RADIATION EFFECTS
CARCINOGENS
CHEMICAL ACTIVATION
COBALT 60
HYDRAZINE
IMMUNOTHERAPY
IRRADIATION
METHYL RADICALS
RATS
SURGERY
ALKYL RADICALS
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL EFFECTS
COBALT ISOTOPES
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MAMMALS
MEDICINE
MINUTES LIVING RADIOISOTOPES
NITROGEN COMPOUNDS
NUCLEI
ODD-ODD NUCLEI
RADIATION EFFECTS
RADICALS
RADIOISOTOPES
RODENTS
THERAPY
VERTEBRATES
YEARS LIVING RADIOISOTOPES
560114* - Radiation Effects on Biochemicals- In Animals- (-1987)
560152 - Radiation Effects on Animals- Animals